Therapeutic Use of LSD in Psychiatry : A Systematic Review of Randomized-Controlled Clinical Trials by Fuentes, Juan José et al.
Frontiers in Psychiatry | www.frontiersin.or
Edited by:
Stefan Borgwardt,












This article was submitted to
Psychopharmacology,
a section of the journal
Frontiers in Psychiatry
Received: 28 August 2019
Accepted: 28 November 2019
Published: 21 January 2020
Citation:
Fuentes JJ, Fonseca F, Elices M,
Farré M and Torrens M (2020)
Therapeutic Use of LSD in





published: 21 January 2020
doi: 10.3389/fpsyt.2019.00943Therapeutic Use of LSD in Psychiatry:
A Systematic Review of Randomized-
Controlled Clinical Trials
Juan José Fuentes1, Francina Fonseca1,2,3, Matilde Elices1,4, Magí Farré5,6
and Marta Torrens1,2,3*
1 Institut de Neuropsiquiatria i Addiccions, Hospital del Mar, Barcelona, Spain, 2 Addiction Research Group (GRAd),
Neuroscience Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain, 3 Psychiatry
Department, Universitat Autònoma de Barcelona (UAB), Cerdanyola del Vallès, Spain, 4 Centro de Investigación Biomédica
en Red de Salud Mental, CIBERSAM, Madrid, Spain, 5 Clinical Pharmacology Department, Hospital Universitari Germans
Trias i Pujol (IGTP), Badalona, Spain, 6 Pharmacology Department, Universitat Autònoma de Barcelona (UAB), Cerdanyola
del Vallès, Spain
Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate
behavioral and personality changes, as well as remission of psychiatric symptoms in
various disorders. LSD was used in the treatment of anxiety, depression, psychosomatic
diseases and addiction. However, most of the studies were not performed under
contemporary standards, and it has taken several decades for a resurgence of interest in
LSD research and its therapeutic potential for psychiatry. The aim of this review is to identify
controlled and randomized clinical trials that assess the potential use of LSD in psychiatry.
PRISMA guidelines for systematic reviewwere followed. A literature search of PubMed and
Psychedelic bibliography from Multidisciplinary Association for Psychedelic Studies
(MAPS) databases was performed as well as a manual search of references from
evaluated studies. Only randomized-controlled clinical trials were included. Study quality
was systematically calculated by using the Cochrane Collaboration Tool for assessing risk
of bias. A final selection of 11 articles was made after considering inclusion and exclusion
criteria. LSD was administered to 567 patients in a dose ranging from 20 to 800 mcg.
Despite the design heterogeneity of clinical trials, positive results were observed, thus
revealing the therapeutic potential of LSD to reduce psychiatric symptomatology, mainly in
alcoholism. The vast majority of authors describe significant and positive short-term
changes in patients, despite the fact that in some studies an important homogenization
was observed between the LSD treatment group and control group at long-term follow-up.
Multiple variables regarding LSD treatment therapeutic approach and quality of experience
were revealed and related to therapeutic outcomes. LSD is revealed as a potential
therapeutic agent in psychiatry; the evidence to date is strongest for the use of LSD in
the treatment of alcoholism. Despite the difficulty of designing proper double blind clinical
trials with this substance, new studies that conform to modern standards are necessary in
order to strengthen our knowledge on its use and open new doors in the future.
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Since its discovery in 1938 by Swiss chemist Albert Hofmann (1),
lysergic acid diethylamide (lysergide, LSD) has maintained an
unstable relationship with psychiatry. Hofmann synthesized LSD
in an effort to develop ergot derivatives with the goal of reducing
postpartum hemorrhage. Some years later, after accidentally
getting into contact with a small dose, he was the first subject
in history to experience its effects (2). At the end of the 1940s,
there was great interest among psychiatrist in the potential use of
LSD as a therapeutic agent (3), which was actually marketed by
Sandoz laboratories under the brand name “Delysid” in the
1950s (4) and used in several psychiatric departments in
Europe and America. Even the US Army and CIA
experimented with this substance as a truth serum, and LSD
was further investigated by the US Army as a potential
incapacitating agent, however without success (5). After its
prohibition in USA in 1967, due to an increase in popularity
and its association with counter-cultural movements, it has taken
several decades for a resurgence of interest in its therapeutic
potential for psychiatry (6–9).
LSD is part of the pharmacological group known as “classical
hallucinogens” or “psychedelics” (term coined by Osmond in
1957) (4), sharing its chemical structure with psilocybin and
dimethyltryptamine (DMT) as a variant of indolamine (chemical
structure similar to the neurotransmitter serotonin) (10).
The term “classical hallucinogen” is a widely accepted
synonym in the literature, with a greater emphasis on the
alteration of the perception that these substances cause (11),
although its use has been controversial as it does not specify the
effect of these agents in consciousness and the self, as indicated
by recent psychological and biological studies (12–14). LSD
could also be defined, from an anthropological perspective, as
an “entheogen”, which implies that users experience (mainly in a
religious, shamanic or spiritual context) an altered state of
consciousness: “as if the eyes had been cleansed and the person
could see the world as new in all respects” (15).
Classical hallucinogens are psychoactive substances that are
believed to mediate their effects mainly through an agonist
activity in the serotonin 2A receptor (5-HT2A) (16).
Experimental studies have previously shown that the use of 5-
HT2A antagonists attenuate the main effects of these substances,
both in rats (17, 18) and human subjects (19–22).
Other receptors which may contribute to the effects of these
agents are the serotonin 2C and 1A receptors, as well as other
effects in the dopaminergic and noradrenergic system (16).
Likewise, these are potent regulators of transcription factors,
which could mediate a potential mechanism of action in the
synaptic structure with greater persistence of their effects over
time (23, 24).
LSD is one of the most potent classical hallucinogens
available, with active doses between 0.5 and 2 mcg/kg (100–
150 mcg per dose). Its half-life is approximately 3 h, varying
between 2 and 5 h, and its psychoactive effects are prolonged over
time (up to 12 h depending on the dose, tolerance, weight andFrontiers in Psychiatry | www.frontiersin.org 2age of the subject) (25, 26). Recently LSD has been used in
microdoses as low as 10 mcg to enhance performance (27).
The usual mental effects of LSD are distortion of sense of time
and identity, alteration in depth and time perception, visual
hallucinations, sense of euphoria or certainty, distorted
perception of the size and shape of objects, movements, color,
sounds, touch and body image and delusions (28).
Concerning safety, the administration of classical
hallucinogens carries some risks. One of them is the so-called
“bad trip” or “challenging experience”, described as an acute state
of anxiety, dysphoria and confusion, which can lead to
unpredictable behavior in uncontrolled or unsupervised
environments (29). Another possible risk is the exacerbation of
psychotic disorders or the generation of prolonged psychotic
reactions, which could be related to the subject's previous
predisposition (30). Although no contemporary study has
reported psychosis after the administration of classical
hallucinogens, an adequate screening of previous psychotic
episodes and the patient's vulnerability is necessary for the use
of these substances (31). Another possible adverse effect is a
modest increase in blood pressure and heart rate; therefore,
patients with severe cardiovascular disease should be excluded
from the administration of this agent. Other usual absolute
contraindications are pregnancy, epilepsy or paranoid
personality traits (32). The remaining adverse effects should
not limit its therapeutic use (31, 33).
As a recreational drug, LSD does not entail physical
dependence as withdrawal syndrome, as do most of these
substances (opioids, cocaine, cannabis and methamphetamine)
(34). Its frequent or long-term use can lead to tolerance, and after
a single dose, emotional, physical and mental stability is quickly
recovered (35, 36). Likewise, classical hallucinogens in general,
and LSD in particular, exhibit very low physiological toxicity,
even at very high doses, without any evidence of organic damage
or neuropsychological deficits (36, 37) associated with their use.
Their safety has recently led to considering LSD as one of the
safest psychoactive recreational substances (38–42).
However, LSD remains one of the most stigmatized and
legally restricted agents among psychoactive substances. It is
still included in Schedule I of the United Nations classification of
drugs, restricting its use in research and making it difficult to
potentially use it as a therapeutic tool in medicine. This
classification has recently been questioned by various authors
(8, 43). A few decades ago, anecdotal reports of suicidal acts in
recreational users were published, and intensely emphasized by
the media (44, 45). These attempts are in contrast with some
recent population studies, which show significant associations
between the use of a single dose of classical hallucinogens and a
decrease in the likelihood of psychological distress and suicide
(46–48). Other recent studies also established a clear link
between life-time use of classical hallucinogens and a lower
probability of developing mental problems, as well as a positive
association, although non-significant, regarding several variables
related to mental health (49, 50). Nevertheless, the
unpredictability of subject behavior makes it necessary toJanuary 2020 | Volume 10 | Article 943
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each individual.
Regarding its therapeutic potential, LSD was used from the
1950s to the 1970s to achieve behavioral and personality changes,
as well as remission of psychiatric symptoms in various disorders
(30, 51). LSD was used in the treatment of anxiety, depression,
psychosomatic diseases and addiction (52). During that time, it
was also observed that LSD together with suitable
accompaniment during its administration, could reduce pain,
anxiety and depression in patients with advanced cancer (53–55)
Other studies involving larger patient samples also established its
safety and promising results in patients with terminal cancer (56,
57). Studies in schizophrenic patients, however, reached less
response to the same dose (58) and worse clinical outcomes (59)
compared with non-schizophrenics patients, and negative effects
on these patients have been described, both in LSD experience
itself and later benefits (60, 61). The data indicate that the
responsivity of schizophrenic patients to the administration of
lysergic acid is less than that of normal subjects.
Prediction of individual responses to LSD depends on several
variables, some of which were already discussed at the
international LSD therapy conference in 1965 (52). LSD
reaction involves a series of complex interactions between
doses, “set” (thoughts, mood and expectations of the subject
prior to treatment) and “setting” (the physical and interpersonal
environment in which the subject undergoes treatment) (30).
Three different major approaches to LSD use as a treatment were
then applied to clinical research: “psycholytic therapy”,
“psychedelic-chemotherapy” and “psychedelic-peak therapy”
(62). In psycholytic therapy, mainly practiced in Europe, low-
moderate doses (25-200 mcg) of this drug were used in more
than one therapeutic session of psychodynamic orientation. In
psychedelic-chemotherapy, drug use itself was emphasized at
relatively high doses (200 mcg or more), with a very limited or
absent psychotherapeutic approach. As for psychedelic-peak
therapy (or “psychedelic therapy”), it involves administering a
single and relatively high dose with the aim of triggering a
mystical-type experience (“peak experience” or “ego
dissolution” as synonyms). This approach should include the
proper prior preparation of the patient (set) and a comfortable
environment during the session (setting), as well as a discussion
on it during subsequent follow-up sessions with the subject
(after-care related to LSD session) (63). Mystical experiences
are referred to as those in which a sense of unity with the
environment is experienced achieving a vivid transcendental
experience at an emotional, cognitive and ego-structural level,
after a previous and personal therapeutic preparation (64). The
aim is to catalyze rapid and fundamental changes in the value
system and self-image of the subject (65).
Despite the foregoing, most clinical studies involving the use
of LSD were published between the 1960s and 1970s, up to the
strict prohibition of its use in research. Obviously, most of these
studies were not performed under contemporary standards. The
purpose of this systematic review is to identify controlled and
randomized clinical trials that assess the potential use of LSD in
psychiatry and identify variables controlled by the researcher asFrontiers in Psychiatry | www.frontiersin.org 3potentially related to therapeutic outcomes. This is with the aim
of informing a discussion on the benefits and challenges of
integrating contemporary classic hallucinogens research into
modern clinical trial designs and providing a guide for further
research involving LSD as a therapeutic agent.METHODS
Data Acquisition and Search Strategy
This study was conducted according to the requirements
established in the Preferred Reporting Items for Systematic
Review and Meta-Analysis (PRISMA) protocols (66).
Pubmed database was searched for the following terms:
[“lysergic acid diethylamide” OR “LSD” OR “lysergic acid
diethylamide” (MeSH Terms)] OR “lysergic acid”) AND
[“therapeutics”(MeSH Terms) OR “mental disorder” (MeSH
Terms) OR “therapy” OR “psychotherapy” OR “treatment”]. In
addition, the Multidisciplinary Association for Psychedelic
Studies (MAPS) Psychedelic Bibliography (www.maps.org) was
also consulted. To ensure literature saturation, the electronic
search was supplemented by a manual review of the reference
lists from eligible publications. Two authors independently
screened the titles and abstracts yielded by the search against
the inclusion criteria. Full reports for all titles that appear to meet
the inclusion criteria were obtained. Reviewers resolved
disagreements by discussion. The search was limited to the
time period compressed between 01-01-1950 and 05-05-2019,
based on the results obtained in the reference search.
Search results were examined by two authors (JJF and FF)
reading the titles and abstracts. Each potentially relevant
publication found during the search was retrieved and assessed
for its use in this review after inclusion and exclusion criteria
were specified.
Data Items
Dosage, frequency and duration of the treatment, for both
experimental and control interventions were extracted.
Patient's characteristics (including age, gender and diagnosis)
and inclusion/exclusion criteria were extracted together with
country, trial design, trial size, and length of follow up. For
non-pharmacological comparators, type, frequency and duration
of the intervention were extracted, if appropriate.
As studies with different diagnostic groups were included,
outcomes varied depending on the psychiatric condition under
study. In any case, change scores from baseline or endpoint were
extracted. Side effects and overall tolerability were also studied.
Eligibility Criteria
Randomized controlled trials of LSD as a therapeutic tool for
psychiatry were included. This review included only randomized
controlled clinical trials involving patients with a diagnosis of
mental illness. Experimental studies in healthy volunteers were
excluded. Trials with no control group or not randomized,
animal studies, observational studies, review papers, qualitative
studies, case reports, opinion pieces or comments, letters orJanuary 2020 | Volume 10 | Article 943
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excluded. Of interest were interventions using LSD, as a stand-
alone treatment or as an adjunctive treatment. Only studies
comparing LSD with other interventions were included. Active
and non-active comparators were included.Quality Assessment
The Cochrane Collaboration risk of bias assessment tool was
used to determine the quality of the studies (67). This tool
involves an assessment of six specific domains: 1) sequence
generation, 2) allocation concealment, 3) blinding of
participants, 4) personnel and outcome assessors, 5)
incomplete outcome data, and 6) selective outcome reporting
and other sources of bias. The tool was applied to each RCT
independently by two authors. Discrepancies were resolved
through discussion with a third author.RESULTS
A total of 3,668 papers were identified through the search in
Pubmed, and 12 additional records were found through other
sources (manual search based on review papers and meta-
analysis). After the removal of duplicates and exclusion based
on titles or abstracts, 43 papers were screened in more detail for
eligibility. Subsequently, another 32 were excluded, which
resulted in the 11 papers used in this systematic review. This
process is described in the PRISMA flowchart (Figure 1). The
quality of the great majority of the clinical trials found did not
conform to modern standards, with a non-randomized control
group or without control group itself. The highest quality of trialsFrontiers in Psychiatry | www.frontiersin.org 4was observed in studies on the therapeutic use of LSD
in alcoholism.
The detailed description of all studies included and their main
results can be found in Tables 1 and 2.
Place and Publication Date of the Study
Among the selected clinical trials, 3 were carried out in Canada, 7
in the USA and 1 in Switzerland. Tables 1 and 2 show these
clinical trials ordered by date of publication. Note the important
41-year interval between the study by (63); and the modern study
by Gasser et al. (75).
Quality Assessment of Studies
A summary of risk of bias is presented in Table 3. Based on the
definitions provided by the Cochrane risk of bias assessment tool
(67), no trials were assessed to show a high risk of bias related to
sequence generation, and all trials used random assignment.
Moreover, all trials attempted to conceal allocation, but most of
them were judged to have unclear risk of allocation concealment
(63, 65, 69, 71–73) because did not describe methods in detail.
Five trials (59, 70, 71, 73, 74) were judged to have a high risk
of bias due to blinding of patients or staff. In two of them (59, 70),
treatment allocation was concealed only until the time of the
possible LSD session, and in the other three trials (71, 73, 74) no
attempt of blindness or to single blind was made or designed.
The rest of them (62, 65, 68, 69, 72, 75) used double-blind
designs with active placebo, but in “Smart et al.” blinding of one
of the two control groups (control group without active placebo)
was not explicitly described.
All trials were judged to have low or an unclear risk
of bias due to independent and blind assessment. In oneFIGURE 1 | PRISMA flowchart of selected abstracts and articles.January 2020 | Volume 10 | Article 943
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as allocation-blind and in another one (59) the assessment
was collected by self-report questionnaire, confirmed by
telephone interview with a close relative or friend. The rest ofFrontiers in Psychiatry | www.frontiersin.org 5them (62, 65, 68–71, 74, 75) had independent and allocation-
blind assessors.
Two trials (62, 72) were judged to have a high risk of bias due
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Fuentes et al. Therapeutic Use of LSDif they did not complete the intended treatment program (72) or
if received additional doses of LSD (62).
Four studies (59, 65, 69, 73) had substantial rates of missing
participants at follow-up. However, retention rates were
generally high, and data missed in one of the trials (63) wasFrontiers in Psychiatry | www.frontiersin.org 6only representative at 12 and 18 months, not at 6 months. In the
other three trials (59, 69, 73), authors considered missing
participants as unimproved.
Three trials (69, 70, 73) were judged to have a high risk of bias
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more detailed data at medium or late-term follow-up. Another
trial (71) was judged to have an unclear risk because some
measures were not strictly reported.
Finally, four trials (62, 65, 71, 74) were judged to have a high
risk of other sources of bias. In one of them (62), due to baseline
imbalance (full-dose LSD participants were less likely to be
divorced and more likely to have prior admissions for alcohol
treatment), other trial (65) due to treatment time (full-dose LSD
participants were more likely to have more psychotherapy hours)
and the rest of them (71, 74) due to a shorter time of
hospitalization [from one day (71) to a few days (74)] for the
LSD treatment group and not the control group. Two last trials
(73, 75) presented unclear risk of bias due to uneven concurrent
use of other pharmacological treatments during study
between participants.
LSD Dosage and Method
LSD was administered to 567 patients in a dose range from 20 to
800 mcg. The oral route was significantly the most used one,
while one study (71) used the intravenous route and another one
(68) did not describe the route used. A single dose of LSD was the
procedure of choice for most selected clinical trials. Other studies
(71, 73) opted for a dosage-escalation approach, and some (73,
75) offered the possibility of repeating LSD doses at 2–3
week intervals.
The concomitant use in some of the studies of other
pharmacological principles, such as dextroamphetamine (73)
prior to the dose of LSD, or chlorpromazine or promazine (71,
73) after LSD treatment is worth mentioning. Since the
therapeutic potential of LSD may be underestimated or
masked by such treatments.
Safety and Adverse Effects
Most studies describe exclusion criteria for patients to be treated
with LSD. Severe organic disease (mainly at neurological and
cardiovascular levels) was a common exclusion criteria (63,
66–69).
“Gasser et al.” do not rule out those patients with
cardiovascular disease, due to the idiosyncrasy of subjectsFrontiers in Psychiatry | www.frontiersin.org 7under study (life-threatening diseases). Two of the studies (67,
75) also excluded those patients with a history of severe affective
disorder. Most clinical trials (65, 68–71, 74, 75) discarded those
patients with active psychosis for the study, but some of them
(65, 68, 70, 74) did not rule out patients with a history of
psychosis in the past. It is noteworthy that in the study of
Tomsovic and Edwards (59), LSD was administered to a
subgroup of 12 patients diagnosed with schizophrenia
(withdrawn from Table 1, due to modern exclusion criteria),
to which they applied a separate statistical analysis that showed
better results for the subgroup of non- schizophrenics who had
received a single LSD dose.
Two cases of serious adverse effects were reported. In one of
the studies (69), authors described a tonic–clonic seizure,
without subsequent complications, in a patient with a previous
history of seizures in a context of abstinent clinical symptoms. In
another one (74), a case of prolonged psychosis was reported in a
21-year-old patient with a previous history of recurrent
psychotic episodes in the context of hospitalization during
adolescence. This patient received psychotherapy and
antipsychotic medicat ion, recovering without later
complications. No other serious adverse effects were described
in the remaining 565 subjects.
Control Group and Active Placebo
Five studies within our review (68, 70–73) designed a control
group for which no drug was administered, and three others
(59, 65, 76) had a control group in which the usual treatment
was applied to patients during hospitalization. In “Savage et al.”
the control group had the added benefit of participating
in one hour and a half group therapy sessions three times a
week, which were defined as eclectic (focused on the solution
of specific problems through group interaction). Most studies
(see Table 1) had a control group in which active placebo
was used, and four of them (62, 65, 72, 75) used LSD itself at a
lower dose. The difficulty in maintaining patient and therapist
uncertainty, even with active placebo, is underlined by authors.
With ephedrine sulfate (68), in 19 of 20 cases the therapist
correctly guessed which type of drug was administered to the



















Smart et al. (68) Low Low Unclear Low Low Low Low
Hollister et al. (69) Low Unclear Low Low Low High Low
Ludwig et al. (70) Low Unclear High Low Low High Low
Hollister et al. (69) Low Unclear High Low Unclear Unclear High
Bowen et al. (72) Low Low Low Unclear High Low Low
Johnson (71) Low Unclear High Unclear Unclear High Unclear
Pahnke et al. (62) Low Unclear Low Low High Low High
Tomsovic and
Edwards (59)
Low Low High Unclear Low Low Low
Savage and McCabe
(74)
Low Low High Low Low Low High
Savage et al. (70) Low Unclear Low Low Low Low High
Gasser et al. (75) Low Low Low Low Low Low UnclearJanuary 2020 | Volume 10 | Article 943
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and therapist.
Treatment Program and “Set”
There was great heterogeneity among the clinical trials chosen
for this review in terms of patient preparation and the general
therapeutic program to which LSD treatment was added. Table 2
shows the type of treatment program used in each study, ranging
from 24 h to 90 days from the start of treatment to patient
discharge. The treatment program between different studies also
differed in structure, varying between highly structured intensive
programs (70) (with five weekly meetings, seminars, group and
individual therapy, occupational therapy and rehabilitation
program) and the absence (73) of a specific program.
Preparation of the subject for LSD treatment ranged from
very brief orientation (68–71 to extensive preparation (62, 65, 74,
75) with the aim of promoting the therapeutic experience.
Preparation time (pre-LSD session, Table 2), ranged from a
few hours to 5 weeks. The only information provided to subjects
in some cases was the great variation in the individual response
of the drug (68), or very brief data on the nature of response (69),
with no intention to perform previous therapy. One of these
authors (70) points out that the previous preparation of patients
to LSD administration was possibly insufficient for achieving
therapeutic objectives.
Despite heterogeneity, there was a trend among most modern
trials within our review to emphasize the importance of the “set”
of the subjects to be studied, devoting more time and providing
them with a structure. In the earliest study meeting these
characteristics (72), patients were previously informed of the
nature of the drug, stating whether they would receive a small or
a large dose. Within the LSD group of treatment (full-dose or
active placebo), approximately half of the patients performed the
session during the first 3 weeks, with the remaining subjects
receiving LSD treatment during the last 3 weeks. There was a
non-significant trend towards better results among those who
received treatment during the last 3 weeks, which was
highlighted by the authors as a positive association between
“set” and therapeutic outcomes.
Therapeutic Approach and “Setting”
Therapeutic Approach
Again, great heterogeneity was observed among studies
regarding the therapeutic approach during the treatment with
LSD. Two studies (68, 71) applied an approach based on active
and directed interviews focused on problems derived from
alcohol dependence. In one of these trials (68), these interviews
were described as an attempt to discover alternatives to alcohol
use, and to define patient attitudes regarding the transfer with the
therapist, the act of moving towards drinking, parental
relationships, suicidal ideation or sexual behavior.
In three of the studies (59, 69, 72), no psychotherapy attempts
were made during the treatment session. In one of them (69), an
effort was made to maintain a supportive environment, which
included non-verbal communication. In another study (70),
three different approaches were used during the LSD session,
defined as “psychedelic therapy”, “hypnodelic therapy” andFrontiers in Psychiatry | www.frontiersin.org 8“silent observation”, to study possible differences in their
therapeutic potential. The author described “an active,
dynamically oriented psychotherapy, with the primary focus
on major problem areas”, which contrast with the description
of “psychedelic therapy” considered above. The most common
approach among these studies (62, 65, 74, 75) was to use
psychedelic therapy, defined as 12-14 h after one relatively
high LSD dose (200-500 mcg), during which a nurse and a
therapist provide constant attention (65) with the aim of the
subject achieving a “peak or transcendental experience” (62).
Setting
Regarding the physical (sensory stimuli) and interpersonal
environment of subjects during the LSD treatment (see Table
2), in five trials (59, 62, 69, 72, 75), musical stimulation during
the session was offered. Descriptions of environment were varied,
finding “comfortable or tastefull furniture” (62, 69, 72) or
“flowers and pictures” (59, 62) as examples. In four of the
studies (65, 70, 73, 74), the physical environment was not
described. Likewise, in two studies (66, 69), the use of waist
belt to bed method was mentioned to prevent subjects from
leaving their position. Regarding the interpersonal environment,
the fact that in the earliest study (68) subjects were
unaccompanied for an indefinite period of time during the
treatment is noteworthy.
Efficacy
The efficacy of the intervention with LSD was presented by the
main diagnosis where the substance was administered.
Alcohol Use Disorder
Most clinical trials in this review (59, 62, 68–73) evaluated the
therapeutic potential of LSD in the treatment of alcohol use
disorder. The main outcomes of these studies and their main
statistical analysis were summarized below, by order
of publication.
In the study by “Smart et al.” there was a substantial
improvement in abstinence (total abstinence and longest
period of abstinence) in all three groups [LSD group (800
mcg), active placebo group (60 mg ephedrine sulfate) and “no
drug” group], but no significant differences were found between
them (ANOVA, p > 0.05). There were no significant differences
between groups either in the Drinking History Questionnaire
nor in number of voluntary contacts with the clinic afterwards.
The second study (69) showed a significant improvement (t-
test, p < 0.01) in the 2-month follow-up in the LSD group with
respect to dextroamphetamine, based on the Drinking Behavior
Scale score. No significant differences were found at 6 months
follow-up, except for two specific symptoms of this scale (related
to work performance), in which LSD was shown to be superior to
dextroamphetamine (chi-square, p < 0.05).
Conversely, in the study by “Ludwig et al.”, results showed a
significant improvement at two weeks of treatment (t-test for
correlated means, p < 0.05) for all four groups (three different
approaches in LSD group (Hypnodelic therapy group,
Psychedelic therapy group and Silent Observation group) and
control group). However, no significant differences were foundJanuary 2020 | Volume 10 | Article 943
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way, a significant improvement (t-test for correlated means,
p < 0.05) was observed in the Behavior Rating Scale values for
each period (6, 12 months) in all groups, without finding
significant differences (ANCOVA, no alpha value reported)
between them.
In the next study (71), a significant improvement was found
in terms of abstinence (ANOVA, p < 0.01), drinking behavior
(ANOVA, p < 0.01) and employment rate (ANOVA, p < 0.05)
after treatment in all groups (LSD treatment group, active
placebo (Sodium Amytal and Methedrine) control group, and
“no drug” control group). However, no significant differences
(chi-square, p > 0.05) were found between them. In the same
direction, in the study by “Bowen et al.”, no significant
differences were found between groups (chi-square, p > 0.05).
In the study by “Denson et al.”, no significant differences (chi-
square, p > 0.05) were observed between groups (LSD group and
control group) at follow-up, except in the Background and
Follow-up Questionnaire for Non-Schizophrenic Patients
(BFQNSP) data, in which the LSD treatment group showed
better results in terms of general health (chi-square, p < 0.05).
In the next study (62), significant improvements were
observed in Global Adjustment (ANCOVA, p < 0.05) and
Drinking Behavior (ANCOVA, p < 0.025) for the LSD
treatment group compared to the control group at 6 months.
Finally, in the last trial (59), a higher percentage of abstinence
was observed among the LSD treatment group compared to
the remaining groups (control group 1: no treatment, only
ongoing follow-up evaluation; control group 2: usual
treatment, “Regular Alcoholic Rehabilitation Program”) at
three months, maintaining this superiority at one year in
several grades. A statistical difference (chi-square p < 0.01) was
observed between the LSD group and the control group 1, but
authors emphasized that the control group 1 was not
representative of the best results observed in the control group 2.
In summary, it was observed a significant effect of LSD in four
studies performed. However, this effect was related to quality of
life and general health in some of the studies, with no clear
improvements in alcohol abstinence.Neurotic Symptoms (Anxiety, Depression, and
Psychosomatic Diseases)
Two trials (65, 73) evaluated LSD as a treatment of neurotic
symptoms. This diagnosis was referred to as depressive neurosis,
obsessive-compulsive reaction, phobic reaction, anxiety state,
hysteria, psychoneurosis with somatic symptoms, character
disorder and sexual neurosis . The presence of al l
symptomatology was not required, and a subset of neurotic
symptoms was adequate. “Denson et al.” found significant
differences (chi-square, p < 0.05) in Questionnaire data
(BFQNSP), in which the LSD treatment group showed better
results in terms of general health at 6 and 12 months. Also, in the
study by “Savage et al.”, a significant improvement (chi-square,
p < 0.05) was observed at 6-8 weeks in most of measurements
used for all three groups (LSD treatment group, active placebo
(LSD) control group and “usual treatment” control group). ThisFrontiers in Psychiatry | www.frontiersin.org 9improvement (mainly focused on symptomatology and self-
actualization) was significantly greater as an average for the
LSD treatment group compared to the “usual treatment” control
group, as well as for some measurements used for the active
placebo (LSD) control group compared to the “usual treatment”
control group. The LSD treatment group showed superiority
(chi-square, p < 0.05) with respect to both control groups in a
sub-scale of the Minnesota Multiphasic Personality Inventory
(F scale, focused on general psychopathology). Regarding
subsequent evaluation (6 months), all groups showed
significant differences in a large number of variables, but in
this case the results of the statistical analysis failed to reach the
defined significance level (ANCOVA, p > 0.05) between
the groups.Heroin Use Disorder
Only one study (74) met the inclusion criteria in our review.
Significant differences were observed (chi square, p < 0.05) in
total abstinence rates in favor of the LSD treatment group at
12 months. A trend, not statistically significant (chi-square, p <
0.02), was observed in favor of the LSD treatment group in
Global Adjustment Rating Scale.Anxiety Associated With Life-Threatening Diseases
A modern study (75) assessed anxiety associated with chronic
inflammatory disease, chronic motor disease and cancer. All
patients had a score of 40 and above in the State-Trait Anxiety
Inventory (STAI). A positive tendency in trait anxiety reduction
(ANOVA, p = 0.033) in the STAI was observed at two months
post ingestion, as well as a significant reduction (ANOVA, p =
0.021) in state anxiety in the STAI. Reduction trends in the STAI
were maintained after 12 months in the LSD group, however
with no significant difference (ANOVA, p > 0.05).
Aftercare Related to Experimental (LSD)
Sessions
In some studies (69, 73) patients could be discharged after 24 h
or in less time (73) if they were able to be assisted by friends or
relatives. Other studies did not specify which patients
maintained subsequent therapy (70), or did not examine
session results unless patients actively requested it (68). In one
of these studies (70), a possibly inadequate follow-up of subjects
was mentioned, without giving them the opportunity to receive
further treatment.
One of the authors (72) suggested that short-term changes
that occurred frequently in subjects' personality could be
integrated and applied to their daily-life insight with greater
support and additional help after hospital discharge. In one study
(65), patients remained hospitalized at least one week after the
LSD session, being visited by their therapists repeatedly. In this
study, a second session with LSD was offered to those patients
who were considered suitable for second exposure
(approximately 25% out of both LSD groups (full-dose and
active placebo) received an equal second dose). In another
study (75), a second dose was also offered to subjects in theJanuary 2020 | Volume 10 | Article 943
Fuentes et al. Therapeutic Use of LSDactive placebo group at months of follow-up (open- label cross-
over design). Finally, in one of trials (70), half of each group was
also treated with disulfiram (daily dose of 500 mg) after hospital
discharge. Patients were strongly encouraged to take a fixed,
prescribed dosage every day, instructed on the dangers of
imbibing alcohol while on disulfiram, and started on the drug
four days prior to hospital discharge. They were given a six-
month supply of disulfiram and instructed to take one 500 mg
tablet per day. Baseline to post-treatment t-tests revealed
significant improvement (t-test for correlated means, p < 0.05)
in Behavior Rating Scale for every group at every period, while
two-way analysis of covariance revealed no significant differences
(ANCOVA, no alpha value reported) between groups that
received disulfiram and those that did not after hospital
discharge, for any of the measurements studied.Variables in Therapeutic Response
Some studies (59, 62, 74) described efforts to predict therapeutic
outcomes in relation to an acute hallucinogen experience. In one
of them (59), it was emphasized that the methodology used did
not manage to measure crucial aspects of the experience that
foresee subsequent benefits. In two others, a significant link was
observed between values in the Global Adjustment Scale (62) and
the probability of optimal adjustment in the community (74) in
relation to the achievement of a “mystical or peak experience”
during the LSD session. One of these authors (62) identified the
LSD dose as a better predictor than the type of experience in his
study; although he also pointed out that there was a close link
between “peak-experiences” and a higher drug dose.
On the other hand, in two studies (59, 74) it was observed that
patients who seemed to benefit from the treatment with LSD did
so optimally with more probability. A greater likelihood of
complete abstinence from alcohol (59) or optimal adjustment
in the community (74) was observed after the LSD treatment.
Finally, one of the authors (65) highlighted that male patients
showed a clear improvement in Global Adjustment with as full
dose (350 mcg) of LSD at six months post ingestion, while in
females, a greater improvement was observed with low doses of
50 mcg (ANCOVA, p < 0.1).DISCUSSION
Despite design heterogeneity among the clinical trials in this
review, some positive results were observed, revealing the
therapeutic potential of LSD in the reduction of psychiatric
symptomatology. The vast majority of authors described
important positive short-term changes in patients, although in
some studies (59, 65, 69) an important homogenization was
observed between the LSD treatment group and the control
group at long-term follow-up. Some previous studies of lower
quality (77) also exemplified a clear improvement in short-term
adjustment, with a later tendency to balance results with the
control group. However, this is in contrast with the results shown
by some authors (62, 74, 75), in which therapeutic changes wereFrontiers in Psychiatry | www.frontiersin.org 10maintained at 6–12 months after treatment. Moreover, in a
follow-up study (78) beneficial changes were found at one year
of follow-up for hallucinogen therapy compared with
conventional psychotherapy in adolescent behavior disorders.
Numerous studies in healthy volunteers have been carried out
within the last decade, and some of them have showed positive
effects more than a year after a LSD or psilocybin single dose
(79, 80).
The results of this review could conclude that alcohol use
disorder patients may benefit from LSD treatment. Other studies
with a lower quality control group (patients did not receive a
treatment comparable to the treatment group) also found
significant differences in favor of LSD treatment in alcoholism
(60, 81). Likewise, according to a retrospective analysis of studies
published in the late 1960s, LSD is a potential therapeutic agent
for the treatment of chronic alcoholism (82). A recent meta-
analysis (83) of six of the clinical trials chosen for this review
showed the superiority of LSD over placebo in the treatment of
alcoholism with an odds ratio (OR) of 1.96 (95% confidence
interval 1.36–2.84 OR, p = 0.0003). This study found that a LSD
single dose was comparable in terms of effectiveness with the
daily intake of naltrexone, acamprosate, or disulfiram in
alcoholism treatment (84–86). Other studies in our review also
found promising results regarding LSD use for the treatment of
heroin use disorder, anxiety, depression, psychosomatic illnesses,
and anxiety in relation to life-threatening diseases. Regarding the
latter, several authors (56, 57) emphasize the difficulty of
designing placebo-controlled and double-blind trials, due to
ethical reasons and the nature of the psychoactive intervention.
Regarding the disparity between some results in our review,
and as noted by Pahnke et al. (62) “it is essential to keep in mind
the differences in procedure among the various methods, not
only because of different kinds of experiences being facilitated,
but also because of conflicting results that can be correlated with
the method used”. LSD invariably involves a complex interaction
between drug dosage, set and setting. This link is also objectified
in different studies, showing the significant relationship between
the therapeutic efficacy of hallucinogens and an adequate set,
setting and integration of later experience (62, 87–90). This could
explain some differences between the results of these reviewed
trials, in which there was a great variation between the approach
of “Smart et al.”, (Psychedelic–chemotherapy: no attempt of
psychotherapy, waist belt) and that of “Savage et al.”
(psychedelic therapy: set, setting and aftercare related to the
LSD session). Some authors (91) argued that the accepted
methods proven to generate some beneficial experience with
LSD are far from those used by Smart at the 1960s. Therefore, the
inherent difficulty in conducting a double blind controlled
clinical trials with LSD should be mentioned. In 1964,
Whitaker (92) stated his opposition to the design of a control
group with this type of substance, due to the promising responses
of first patients as opposed to the control group. Due to this
difficulty, widely discussed at the time, many studies previous to
that carried out by “Smart et al.”, did not apply adequate
measures or assessments, without a control group or properly
designed statistical analysis. In this regard, Tomsovic andJanuary 2020 | Volume 10 | Article 943
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achieving control over the placebo effect of a drug that has
spectacular mind-altering properties, and where research is
contaminated by expectations of benefit”.
Also, modern clinical trials are currently facing a series of
problems, which could be summarized as follows (93). Firstly,
subjective and objective changes experiencedwith LSD and the rest
of hallucinogens, apparent for both the subject and observer, make
performing double-blind tests virtually impossible. Likewise,
adequate placebo control becomes extremely difficult due to the
absence of such changes in the control group. Strict control of the
variables related to the therapeutic benefits of LSD is also necessary.
Finally, research with these substances must overcome a series of
strict ethical committees and restrictions at the legal level.
When attempting to solve difficulties in terms of blinding and
adequate placebo control, a valid approach is an active placebo,
using LSD at lower doses (94), an approach already suggested
within some of clinical trials in our review (62, 65). This
methodology, despite possibly minimizing the effects of LSD
when compared to its sole administration, is based on results by
numerous researchers who have observed the link between dose
and quality and intensity of the hallucinogen response (95–98).
Dosage and form of administration, as well as the context in
which it is carried out, can be strictly controlled within a hospital
setting. The possible effects of microdoses of LSD must be takin
into account, possibly limiting its use.
Despite the known unpredictability of hallucinogens, great
efforts have been made in recent years to know which variables
are associated with the therapeutic value of these substances,
finding mystical-type experiences as one of the objectives to be
achieved (97, 99, 100). Results of recent investigations show that
mystical-type experiences are associated with positive long-term
changes after a dose of hallucinogens (33, 79, 99–102). The
musical stimuli variable has also been observed as a predictor of
mystical-type experiences and positive therapy outcomes (103).
As noted by Gasser (76), designing qualitative studies,
not only based on pathology-oriented measurements,
is also important to detect variables related to other
psychopathological symptoms that can potentially be
improved by LSD use (e.g. equanimity, self- assurance and
mental strength). Currently, there are validated scales available
to measure the quality of the hallucinogen experience, such as
the Mystical Experience Questionnaire (MEQ-30) (104) and
the Ego-Dissolution Inventory (EDI) (96). The apparently
unpredictable nature of these experiences makes studying
them in empirical research equally difficult and necessary
(14, 104, 105).
Moreover, numerous recent studies with LSD regarding
changes in neural networks have been carried out. Modularity
and integration networks (as observed in resting- state functional
connectivity) have been shown to decrease due to effects of LSD
(106, 107). Patterns compared to normal waking consciousness
have been demonstrated with LSD (108), and a correlation
between subjective reports of “ego dissolution” during LSD and
an increment of the overall connectivity and global integration of
the brain was found (109). These changes at the cerebral levelFrontiers in Psychiatry | www.frontiersin.org 11during the acute effects of hallucinogens have been associated
with the aforementioned subjective effects “ego dissolution” and
“mystical-type”, and could be related to the wide therapeutic
value of these substances (101, 102, 105, 110).
Likewise, multiple modern clinical trials involving other
hallucinogens have been carried out in the last decade, mainly
with psilocybin. Hopeful results have been found for the
treatment of alcohol (111) or tobacco (112) addiction,
anxiety in relation to advanced cancer (113) or obsessive-
compulsive disorder (114). Moderate doses of psilocybin (200
µg/kg) have been used in some modern studies, either with dose
escalation (114) or the same dose in various sessions (113),
something reminiscent of the psycholithic therapy used in
Europe in the past century. Some possible reasons for the
greater use of psilocybin over LSD in modern trials were the
shorter duration of one effects of the former (thus avoiding
hospitalization) or the greater stigma that prevailed regarding
the latter (making it difficult to get economic funds and the
approval by ethical committees). Beyond psychiatry, the
therapeutic potential of LSD in other medicine fields has
recently become evident, as in the treatment of cluster
headaches in neurology (115).
As it has been previously pointed out, the homogenization of
the therapeutic approach is strictly necessary, and training
programs related to research and psychotherapy with
hallucinogens have recently been developed (116). Also, there
are modern guidelines available for the correct use of
hallucinogens in clinical research (31). Therefore, the reborn
interest of the therapeutic potential of hallucinogens in modern
clinical trials is evident, something proven by the remarkable
increase in the number of studies carried out with these
substances over the last decade (117).
The present review has limitations. Firstly, only articles
written in English were selected; this could imply that articles
in other languages were excluded despite the fact that these
might have provided valuable information. Furthermore, as
mentioned above, most studies were carried out during the
past century. Moreover and as previously discussed, there was
considerable heterogeneity in their design. Also, differences
regarding patient populations, features, and diagnostic
methods were noticed. Therefore, due to the lack of studies
and the features exhibited by selected research, this review can
contribute limited evidence on the topic of interest.
This study comes with its own set of strengths. On the one
hand, to our knowledge this is the first systematic review of
randomized-controlled trials to assess the therapeutic potential
of LSD in psychiatry. On the other, a strict selection of studies
was carried out, considering inclusion and exclusion criteria as
well as confounding factors. With regards to this and in spite of
the heterogeneity mentioned above, the important therapeutic
value of LSD is revealed and it is observed to be related to
variables controlled by the researcher, such as: set, setting and
aftercare related to the LSD session. Another positive aspect of
this review is that our results highlight the need for randomized-
controlled clinical trials with standardized methods to accurately
assess the quality of an acute hallucinogen experience. Finally,January 2020 | Volume 10 | Article 943
Fuentes et al. Therapeutic Use of LSDthis review could serve as a guide for further research involving
LSD as a therapeutic agent.
CONCLUSIONS
In conclusion, and despite some controversial results mentioned
above, LSD is revealed as a potential therapeutic agent in
psychiatry; the evidence to date is strongest for the use of LSD
in the treatment of alcoholism. Despite the difficulty of designing
double-blind clinical trials with this substance, new studies
performed under modern standards are necessary in order to
strengthen our knowledge, help erase the stigma that still prevails
around these substances and open new doors in the future.AUTHOR CONTRIBUTIONS
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